pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › PDUFA Calendar › BCDA

BioCardia, Inc. (BCDA) FDA catalysts & readout calendar

Page updated ·next FDA decision on the calendar ·Data as of Nov 12, 2026 2:24 AM ET
BioCardia, Inc. · no upcoming catalyst on file · 0 past FDA decisions

Clinical readouts (1)

2026-12Autologous cell therapy
Full PDUFA calendar →All FDA decisions →Phase readouts →
See the full 2026 PDUFA calendar →

This page aggregates BCDA's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.

Common questions

When is the next FDA decision or readout for BioCardia, Inc. (BCDA)?

December 2026. The next catalyst for BioCardia, Inc. is Autologous cell therapy (readout). That date is known to the month only. Dates are taken from FDA notices, company filings or ClinicalTrials.gov, and we do not publish a specific day when the source only gives a month or a quarter.

How do stocks like BCDA move into an FDA decision?

We have no measured history for BCDA itself. Across the whole study of 1,885 FDA decisions, the median stock rose 18.0% at its best point in the 120 trading days before the decision, but was only 2.4% higher the day before it. Most of the move happened before the answer arrived and was largely given back.

Where does this BCDA data come from?

FDA publications, company filings with the SEC, company press releases and ClinicalTrials.gov, with share prices measured from daily closing data. Every date and outcome links the document it came from. Where an outcome was inferred from the price reaction rather than read from a filing, the page says so on its face.